View clinical trials related to Covid19.
Filter by:Racial and ethnic minority children who live in socioeconomically disadvantaged communities are disproportionately impacted by pandemic and climate-induced disasters. Although effective interventions have been designed to treat mental health related symptoms in post-disaster settings, accessible, empirically supported prevention interventions are needed to prevent the onset of mental and behavioral health issues among these children. Building on our preliminary findings, the proposed study examines the efficacy and implementation of a COVID-19 adapted disaster focused prevention intervention, Journey of Hope-C19, in preventing behavioral health and interpersonal problems among racial and ethnic minority children who live in low-resource high poverty communities.
The goal of this interventional study is to investigate whether continued use of regular asymptomatic testing in staff is a feasible, effective and cost-effective strategy to reduce the impact of COVID-19 in care homes. The trial aims to quantify the benefits and harms of regular asymptomatic testing in care home staff to inform policy. The rationale for regular asymptomatic testing is that it may reduce the risk of severe disease in residents and the frequency/severity of outbreaks. Participants (care home staff) will perform regular asymptomatic tests for Covid-19. Should they test positive they will be required to refrain from working and be provided with sick pay. Care providers will be reimbursed for the costs of employing agency staff to cover staff sickness absence that results directly from the trial.
This clincial trial is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial in hospitalized patients with moderate to severe COVID-19 corresponding to score 5 or 6 on the WHO 10-point clinical progression scale (Grade 0-10). The investigational drug (APG101; International Nonproprietary Name: asunercept) will be given at a dose of 100 mg intravenously (i.v.) once weekly for a period of 4 weeks (1 dose each on d1, d8, d15, and d22) in addition to the treatment recommended by international, national, or local treatment guidelines (SoC) and will be compared with the control arm (i.e., SoC + placebo).
This is a Phase 2, randomized, double-blind, multicentre, placebo-controlled study in adults to assess the safety and efficacy of inhaled IBIO123, for post-exposure prophylaxis of COVID-19. This study aims to evaluate the efficacy and the safety of IBIO123 and the prophylaxis effect of IBIO123 in participants exposed to COVID-19 in the setting of current and uninterrupted household contacts.
To apply and compare two different methodological approaches (one applying diagnostics steps and contingencies and the other not) to the illustrative example described below: Illustrative Example - Objective I aims to characterize the risk of inpatient mortality [Primary Outcome] and progression to invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) [Secondary Outcome] up to 28 days after interleukin-6 receptor inhibitors (IL6Ri) or janus kinase inhibitor (JAKi) initiation among patients hospitalized with COVID-19 who initiate a corticosteroid of interest and require supplemental oxygen / non-invasive ventilation / high flow oxygen (O2/NIV/HFO) (but not IMV/ECMO). Illustrative Example - Objective II aims to characterize the risk of inpatient mortality [Primary Outcome] up to 28 days after IL6Ri or JAKi initiation among patients admitted to the ICU at hospital admission with COVID-19 who initiate a CSI and require IMV/ECMO. Hazard ratios (HR) and corresponding 95% confidence intervals (CI) will be estimated and reported for all outcome risks in Illustrative Example objectives.
This study is a prospective observational cohort study to evaluate the benefit of oral antivirals (nirmatrelvir plus ritonavir or molnupiravir) in Ministry of Health institutions. In this study, we will observe the progress of COVID-19 study participants seen in the health clinic up to 90 days from their initial visit to the health clinic.
Long COVID refers to persistent symptoms after a generally mild acute COVID-19. Because the symptoms are often complex and vary from person to person, the term post-COVID syndrome is used synonymously. In the ICD-10 catalog, Long COVID is mapped as U09.9 as "post-COVID-19 conditions." Long COVID carries a high risk for chronic morbidity. This has serious consequences for individuals and society, especially when manifesting in young adulthood, adolescence, and childhood. Current data show that predominantly young women aged 30-40 years are affected by severe Long COVID. Despite only mild acute COVID-19, 10-15% of patients still show persistent symptoms six months later, including particularly frequently pathological exhaustion (fatigue), exercise intolerance with symptom worsening after exertion (so-called post-exertional malaise), neurocognitive complaints and circulatory disorders. In addition, general symptoms such as sleep disturbances, pain, or subfebrile temperatures have been described, as well as symptoms of all organ systems. In children and adolescents, less prevalence data are available to date. In initial studies, 4.4% and 4.6% of children and adolescents, respectively, show persistent symptoms after four weeks, 9.8% of 2-11 year olds and 13% of 12-16 year olds after five weeks, and 1.8% of children and adolescents with confirmed/probable SARS-CoV-2 infection after two months. Long COVID often results in impairment of daily life with limited ability to go to school or to work, up to and including inability to go to school or to work. Some patients manifest full-blown CFS, which has also been described after other viral infections, such as after glandular fever caused by Epstein-Bar virus (EBV). Similar to post-COVID CFS, CFS after primary EBV infection manifests predominantly in female adolescents and young adults. Whether it is the same severe, chronic disease despite similar clinical phenotype is uncertain. The mechanisms of pathogenesis of Long COVID and postinfectious CFS have been poorly elucidated. Initial studies of Long COVID suggest that autoimmunity, chronic inflammation, endothelial dysfunction, and psychosocial aspects contribute to pathogenesis. For postinfectious CFS, a causal interplay of genetic factors, stress, and infections has also been postulated, inducing a vicious cycle of dysregulation of the central and autonomic nervous system, immune defense, and metabolism.
Since December 2019, a new corona virus (SARS-CoV-2) causing COVID-19 disease, has expeditiously spread over the entire globe. Almost a half billion people caught the disease, and in those who survived, it soon became clear that residual complaints are not rare phenomena. Early focus lay on diminished lung capacity and cardiovascular-related problems. As time passed however, it became more apparent that those are not the only residual symptoms survivors may experience. Furthermore, nearly every country in the world took some sort of lockdown measures in order to try contain the spreading of the virus. These measures had great impact on all inhabitants, infected with the virus or not. This questionnaire-based study therefore aims to investigate (a) the effects of a COVID-19 infection on fatigue and/or musculoskeletal complaints, new or already existing, but also (b) the effects of lockdown measures on fatigue and/or musculoskeletal complaints, new or already existing, in people living, working or studying in Belgium during the pandemic.
Combined with the regional and population characteristics of Asia and Africa, Huashi Baidu Granule was used to intervene in mild and ordinary patients with COVID-19, evaluate its efficacy and safety, and clarify its characteristics of action.
This is a multicenter, randomized, placebo controlled, double-blind phase III trial with four parallel groups studying studying the feasibility of RCT in primary care as well as the effectiveness of treatment with prednisolone and/or vitamin B1/6/12 for PC19S.